AstraZeneca/Ionis heart-failure drug Wainua fails pivotal trial as White House reviews FDA commissioner candidates

The White House is reviewing a shortlist of three candidates for the FDA commissioner position, according to STAT. The list includes White House adviser Heidi Overton, oncologist and health‑system executive Jeffrey Vacirca, and Defense Department health‑affairs official Stephen Ferrara. Acting commissioner Kyle Diamantas has been in the role since Marty Makary resigned earlier this year.

AstraZeneca and Ionis announced that their heart‑failure drug Wainua did not meet its primary endpoint in a pivotal trial, a setback that undercuts the companies' expectations for the product. The failure was described as a core disappointment, given the drug was central to AstraZeneca’s goal of reaching $80 billion in annual sales.

The trial result sent both stocks lower and prompted analysts to cite the outcome as part of a broader trend of recent regulatory approvals and setbacks. Investors and industry observers will be watching how the companies adjust their development plans and how the FDA commissioner selection may influence future regulatory landscapes.